Drugs / MAG-Tn3
last change Nov 2021 re-read 2 minutes ago

MAG-Tn3

Vaccine

Developed for
breast cancer
Investigated by
Institut Pasteur

Trials 1 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02364492 Feb 2015 → Oct 2019 breast cancer Institut Pasteur Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MAG-Tn3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02364492
Modality Vaccine “The fully synthetic glycopeptide vaccine MAG-Tn3” PMID 32034426 Feb 2020